Cancer Clinical Trials Available in the South Chicago Suburbs

USOR 17079 – FLEX Registry: Evaluate New Gene Expressions

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)

Available at Chicago Ridge, Orland Park

USOR 22297 - Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)

A Phase III, Open-Label, Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Available at Chicago Ridge, Orland Park

USOR 23189 - Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)

A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)

Available at Chicago Ridge, Orland Park

USOR 22285 - MYLUNG Consortium Part 3: Observational Study

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)

Available at Chicago Ridge, Orland Park

USOR 24149 (LUN 572): Ph3 Study of Nivolumab + Relatlimab Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy

A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49%.

Available at Chicago Ridge, Orland Park

STAR: SELECTED TRIALS AVAILABLE FOR ACCELERATED FOUR WEEK ROLLOUT

USOR 19151 - STAR: Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Available at Chicago Ridge, Orland Park

USOR 24169 (MULTI 88) : Ph2 Study of Zanidatamab for Previously Treated HER2-expressing Solid Tumors

A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants with Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)

Available at Chicago Ridge, Orland Park